NewsBenzingaB. Riley Securities maintient son avis d'achat sur Elicio Therapeutics, mais abaisse l'objectif de prix à 8 $. B. Riley Securities maintient son avis d'achat sur Elicio Therapeutics, mais abaisse l'objectif de prix à 8 $. Benzinga 2026.09.24 14:16 (GMT+0) Open on Benzinga Other news AI models can be tricked into identifying civilians as military targets by telling them it’s a game Why Nvidia Is Falling Tuesday: Jensen Huang’s Comeback Statement, Congress Hearings, and AI Risks General Motors Plans 20% Boost In Robotics As Factory Costs Rise Eli Lilly Inks Multibillion-Dollar Pact to Develop Precision Cancer Therapies McKesson Stock Is a Triple Threat at New All-Time Highs. How to Trade It Here. 'Nvidia stopped disclosing Singapore sales as revenues hit $104B' -FT